10-Q · August 4, 2026
Addus delivered an 8.0% year-over-year increase in Q2 revenue to $377.417 million and expanded operating margin to 10.3% from 9.4%, with diluted EPS of $1.73. Personal care was the principal growth engine, while hospice…
Earnings analysis · 10-Q
Filed November 4, 2026 · Our reading of the company's report
The latest report
Addus delivered solid operating momentum in Q3 2026: revenue rose 7.0% year over year to $387.733 million and EPS of $1.83 exceeded consensus by $0.07, while adjusted EBITDA rose 13.5% to $51.249 million. Revenue…
Addus delivered solid operating momentum in Q3 2026: revenue rose 7.0% year over year to $387.733 million and EPS of $1.83 exceeded consensus by $0.07, while adjusted EBITDA rose 13.5% to $51.249 million. Revenue modestly missed estimates and the filing does not provide current-quarter gross margin, operating margin, free cash flow, or segment revenue data. The pending approximately $275 million AccentCare acquisition is the principal forward catalyst and risk, with regulatory, closing, integration, and financing considerations.
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Revenue was $387.733 million, up approximately 2.8% from $377 million in Q2 2026 and 7.0% from $362 million in Q3 2025, although it was approximately $0.891 million below the $388.624 million consensus estimate.
Actual EPS was $1.83 versus the $1.76 consensus estimate, a $0.07 beat or approximately 4.0%. EPS increased from $1.49 in Q2 2026 and $1.24 in Q3 2025.
Adjusted EBITDA increased 13.5% to $51.249 million, indicating earnings growth outpaced the 7.0% year-over-year revenue increase.
The company entered into an agreement to acquire AccentCare’s personal care division for approximately $275.0 million; the transaction is expected to add approximately $280 million of annualized revenue if completed.
Management stated that disclosure controls and procedures were effective as of September 30, 2026, and reported no changes in internal control that materially affected or were reasonably likely to materially affect financial reporting during the quarter.
The AccentCare acquisition has an approximately $275.0 million purchase price and remains subject to regulatory approvals and other closing conditions. The company states it may fail to complete the transaction on time or at all and would still bear transaction costs if it does not close.
The company expects integration expenses and identifies potential unanticipated problems, expenses, liabilities, regulatory risks, and management distraction. The expected acquisition benefit of approximately $280 million in annualized revenue may therefore be delayed, reduced, or not realized.
As of September 30, 2026, approximately $24.3 million was outstanding on the variable-rate credit facility. A 100-basis-point increase in variable rates would have reduced nine-month net income by $0.4 million, or $0.02 per diluted share; the company has no interest-rate hedges.
No formal numeric EPS or revenue guidance was provided. The pending AccentCare acquisition is expected to add approximately $280 million of annualized revenue for an anticipated purchase price of approximately $275 million.
Addus delivered an 8.0% year-over-year increase in Q2 revenue to $377.417 million and expanded operating margin to 10.3% from 9.4%, with diluted EPS of $1.73. Personal care was the principal growth engine, while hospice…
Addus HomeCare Corporation reported solid Q1 2026 results with revenue of $363.6 million and EPS of $1.62, marking an 18.1% and 4.128% increase from the prior year respectively. While operating income rose 11.7%, the…
Addus reported 2025 net service revenue of $1,422,530,000 versus $1,154,599,000 in 2024 (a $267,931,000 / +23.2% increase) and net income of $95,910,000 in 2025 versus $73,598,000 in 2024. Growth was driven by the…
Addus reported revenue of $280.7M for the quarter ended March 31, 2024, up $29.1M (+11.6%) versus the prior-year quarter, with gross profit rising to $88.2M and operating income to $23.6M. Diluted EPS increased to $0.97…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.